Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropharmacology ; 128: 388-400, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29104074

ABSTRACT

Anxiety disorders represent serious social problems worldwide. Recent neuroimaging studies have found that elevated activity and altered connectivity of the insular cortex might account for the negative emotional states in highly anxious individuals. However, the exact synaptic mechanisms of specific insular subregions have yet to be studied in detail. To assess the electrophysiological properties of agranular insular cortex (AIC) neurons, basic synaptic transmission was recorded and different protocols were used to induce presynaptic and postsynaptic long-term potentiation in mice with anxiety-related behaviors. The presynaptic membrane expression of kainate receptors (KARs) and pharmacologic manipulations were quantified to examine the role of Gluk1 subtype in anxiety-like behaviors. Fear conditioning occludes electrically induced postsynaptic-LTP in the AIC. Quantal analysis of LTP expression in this region revealed a significant presynaptic component reflected by an increase in the probability of transmitter release. A form of presynaptic-LTP that requires KARs has been characterized. Interestingly, a simple emotional anxiety stimulus resulted in selective occlusion of presynaptic-LTP, but not of postsynaptic-LTP. Finally, injecting GluK1-specific antagonists into the AIC reduced behavioral responses to fear or anxiety stimuli in the mouse. These findings suggest that activity-dependent synaptic plasticity takes place in the AIC due to exposure to fear or anxiety, and inhibiting the presynaptic KAR function may help to prevent or treat anxiety disorder.


Subject(s)
Anxiety/pathology , Cerebral Cortex/physiology , Fear/psychology , Long-Term Potentiation/physiology , Receptors, Kainic Acid/metabolism , Animals , Cerebral Cortex/drug effects , Cerebral Cortex/pathology , Conditioning, Classical/drug effects , Conditioning, Classical/physiology , Disease Models, Animal , Disks Large Homolog 4 Protein/metabolism , Excitatory Amino Acid Agents/pharmacology , Exploratory Behavior/drug effects , Glutamic Acid/pharmacology , Male , Maze Learning/drug effects , Maze Learning/physiology , Membrane Potentials/drug effects , Mice , Mice, Inbred C57BL , Neurons/drug effects , Synaptosomal-Associated Protein 25/metabolism , Valine/analogs & derivatives , Valine/pharmacology
3.
Behav Brain Res ; 232(1): 245-51, 2012 Jun 15.
Article in English | MEDLINE | ID: mdl-22537774

ABSTRACT

Repetitive transcranial magnetic stimulation (rTMS) has been demonstrated in the pre-clinical and clinical settings to have an antidepressant effect. However, studies on the long-lasting effect of rTMS, especially when the effect is measured after treatment has ceased for a few weeks is lacking. We examined this question in a chronic unpredicted mild stress (CUMS) rat model of depression. We gave 3 weeks of high frequency (15 Hz) rTMS, venlafaxine, or these two treatments combined to a modified CUMS paradigm, and then investigated the prolonged effect of treatments. Behavioral testing (sucrose preference test, open field test, forced swimming test, novelty suppressed feeding test), plasma hormone level, hippocampal BrdU labeling, and amount of related neurotropic factors were used to assess the effects of stress and treatments. Long-term chronic rTMS significantly reversed andehonic-like behavior, increased hippocampus cell proliferation, BDNF protein level, phosphorylation of ERK1/2 compared with CUMS rats two weeks after the cessation of rTMS treatment. However, the changes in plasma hormone level were not sustained for that amount of time. Venlafaxine had no interaction with the physical stimulation. Our results suggest that high frequency rTMS has long-lasting effects, which may have some relationship with neuroplasticity.


Subject(s)
Depression/psychology , Depression/therapy , Transcranial Magnetic Stimulation , Adrenocorticotropic Hormone/blood , Anhedonia , Animals , Antidepressive Agents, Second-Generation/therapeutic use , Antimetabolites , Blotting, Western , Body Weight/drug effects , Body Weight/physiology , Brain/anatomy & histology , Brain/drug effects , Brain-Derived Neurotrophic Factor/metabolism , Bromodeoxyuridine , Cyclohexanols/therapeutic use , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Food Preferences/drug effects , Food Preferences/physiology , Hydrocortisone/blood , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Male , Motor Activity/drug effects , Motor Activity/physiology , Neurogenesis/drug effects , Rats , Rats, Sprague-Dawley , Selective Serotonin Reuptake Inhibitors/therapeutic use , Stress, Psychological/complications , Stress, Psychological/psychology , Swimming/physiology , Swimming/psychology , Venlafaxine Hydrochloride
4.
J Neurosci ; 32(14): 4887-900, 2012 Apr 04.
Article in English | MEDLINE | ID: mdl-22492045

ABSTRACT

17-ß-estradiol (E2) is a steroid hormone involved in neuroprotection against excitotoxicity and other forms of brain injury. Through genomic and nongenomic mechanisms, E2 modulates neuronal excitability and signal transmission by regulating NMDA and non-NMDA receptors. However, the mechanisms and identity of the receptors involved remain unclear, even though studies have suggested that estrogen G-protein-coupled receptor 30 (GPR30) is linked to protection against ischemic injury. In the culture cortical neurons, treatment with E2 and the GPR30 agonist G1 for 45 min attenuated the excitotoxicity induced by NMDA exposure. The acute neuroprotection mediated by GPR30 is dependent on G-protein-coupled signals and ERK1/2 activation, but independent on transcription or translation. Knockdown of GPR30 using short hairpin RNAs (shRNAs) significantly reduced the E2-induced rapid neuroprotection. Patch-clamp recordings revealed that GPR30 activation depressed exogenous NMDA-elicited currents. Short-term GPR30 activation did not affect the expression of either NR2A- or NR2B-containing NMDARs; however, it depressed NR2B subunit phosphorylation at Ser-1303 by inhibiting the dephosphorylation of death-associated protein kinase 1 (DAPK1). DAPK1 knockdown using shRNAs significantly blocked NR2B subunit phosphorylation at Ser-1303 and abolished the GPR30-mediated depression of exogenous NMDA-elicited currents. Lateral ventricle injection of the GPR30 agonist G1 (0.2 µg) provided significant neuroprotection in the ovariectomized female mice subjected to middle cerebral artery occlusion. These findings provide direct evidence that fast neuroprotection by estradiol is partially mediated by GPR30 and the subsequent downregulation of NR2B-containing NMDARs. The modulation of DAPK1 activity by GPR30 may be an important mediator of estradiol-dependent neuroprotection.


Subject(s)
Estrogens/pharmacology , Neuroprotective Agents/pharmacology , Receptors, G-Protein-Coupled/physiology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/metabolism , Animals , Animals, Newborn , Cell Survival/drug effects , Cell Survival/physiology , Cells, Cultured , Down-Regulation/drug effects , Down-Regulation/physiology , Female , Male , Mice , Mice, Inbred C57BL , Phosphorylation/drug effects , Phosphorylation/physiology , Receptors, Estrogen , Time Factors
5.
Schizophr Res ; 137(1-3): 97-103, 2012 May.
Article in English | MEDLINE | ID: mdl-22341901

ABSTRACT

OBJECTIVE: Previous studies have demonstrated the effectiveness of electroconvulsive therapy (ECT) in pharmacotherapy-resistant neuropsychiatric conditions. This study aimed to evaluate the efficacy and safety of ECT in adolescents with first-episode psychosis. METHOD: This case-control study was conducted in inpatients aged 13-20 years with first-episode psychosis. Every three similar age and same gender patients consecutively recruited were randomly allocated to control and ECT group at a ratio of 1:2, while they had antipsychotic treatment. ECT treatment was performed for 3 sessions per week with a maximum of 14 sessions. The endpoint was discharge from hospital. Clinical outcomes were measured using hospital stay days, the Positive and Negative Syndrome Scale (PANSS) and response rate. Polysomnography (PSG) was conducted at baseline and at week 2. Safety and tolerability were also evaluated. RESULTS: Between March 2004 and November 2009, 112 eligible patients were allocated to control (n=38) and ECT (n=74) group. Additional ECT treatment significantly reduced hospital stay compared to controls (23.2±8.2 days versus 27.3±9.3 days, mean±SD, P=0.018). Survival analysis revealed that the ECT-treated group had a significantly higher cumulative response rate than controls (74.3% versus 50%, relative risk (RR)=1.961, P=0.001). Additional ECT also produced significantly greater improvement in sleep efficiency, rapid eye movement (REM) latency and density than control condition. The PSG improvement significantly correlated with reduction in scores on overall PANSS, positive symptoms, and general psychopathology. No patients discontinued ECT treatment regimen during hospital stay. The incidence of most adverse events was not different in the two groups, but ECT-treated group had more complaints of transient headache and dizziness than controls. CONCLUSIONS: ECT is an effective and safe intervention used in adolescents with first-episode psychosis. Its antipsychotic effects are associated with improved PSG variables. ECT can be considered as an early psychosis intervention.


Subject(s)
Antipsychotic Agents/therapeutic use , Electroconvulsive Therapy/methods , Psychotic Disorders/therapy , Sleep Wake Disorders/etiology , Sleep Wake Disorders/therapy , Adolescent , Case-Control Studies , Female , Humans , Kaplan-Meier Estimate , Male , Polysomnography , Retrospective Studies , Sleep, REM/drug effects , Sleep, REM/physiology , Treatment Outcome , Young Adult
6.
Neurotox Res ; 21(4): 358-67, 2012 May.
Article in English | MEDLINE | ID: mdl-22095090

ABSTRACT

Salidroside (Sal) is a natural antioxidant extracted from the root of Rhodiola rosea L. that elicits neuroprotective effects in vivo and in vitro. Tyrosol galactoside (Tyr), an analog of Sal, was recently synthesized in our laboratory. The purpose of the current study was to investigate and compare the neuroprotective effects of Sal and Tyr against focal cerebral ischemia in vivo and H(2)O(2)-induced neurotoxicity in vitro. Sal and Tyr significantly prevented a cerebral ischemic injury induced by a 2 h middle cerebral artery occlusion and a 24 h reperfusion in rats in vivo. Furthermore, the oxidative insult was markedly attenuated by treatments of Sal and Tyr in the cultured rat cortical neurons after a 30 min exposure to 50 µM of H(2)O(2). Western blot analysis revealed that Sal and Tyr decreased the expression of Bax and restored the balance of pro- and anti-apoptotic proteins. The neuroprotective effects of these two analogues show that Tyr has a better antioxidative action compared with Sal both in vivo and in vitro, and suggest that the antioxidant activity of Sal and Tyr may be partly due to their different substituents in their glycosyl groups. This gives a new insight into the development of therapeutic natural antioxidants against oxidative stress.


Subject(s)
Brain Ischemia/drug therapy , Galactosides/therapeutic use , Glucosides/therapeutic use , Hydrogen Peroxide/antagonists & inhibitors , Neuroprotective Agents/therapeutic use , Phenols/therapeutic use , Phenylethyl Alcohol/analogs & derivatives , Animals , Apoptosis Regulatory Proteins/metabolism , Brain Ischemia/pathology , Cell Survival/drug effects , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Disease Models, Animal , Drug Administration Schedule , Galactosides/administration & dosage , Galactosides/pharmacology , Glucosides/administration & dosage , Glucosides/pharmacology , Hydrogen Peroxide/toxicity , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/pathology , Male , Neurons/metabolism , Neurons/pathology , Neuroprotective Agents/pharmacology , Oxidants/antagonists & inhibitors , Oxidants/toxicity , Phenols/administration & dosage , Phenols/pharmacology , Phenylethyl Alcohol/administration & dosage , Phenylethyl Alcohol/pharmacology , Phenylethyl Alcohol/therapeutic use , Primary Cell Culture , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Reperfusion Injury/drug therapy , Reperfusion Injury/pathology , bcl-2-Associated X Protein/biosynthesis
7.
Prog Neuropsychopharmacol Biol Psychiatry ; 34(6): 1018-25, 2010 Aug 16.
Article in English | MEDLINE | ID: mdl-20493230

ABSTRACT

The present study examined the protective effect of hyperbaric oxygen preconditioning (HBO-PC) and the role of thioredoxin reductase (TrxR) in a post-traumatic stress disorder (PTSD)-induced rat model by using single prolonged stress (SPS). Rats were randomly divided into Sham, HBO, SPS and HBO+SPS groups. HBO-PC was conducted by exposing rats to 100% oxygen at 2.5atm absolute for 1h each day for 5 consecutive days. SPS was performed 24h after the last HBO-PC conditioning event. At 1h, 6h, 12h, 24h and 72h after SPS, TrxR mRNA expression was analyzed in the hippocampus; Nissl and TUNEL staining were performed at 72h after SPS. The results indicated that HBO-PC was able to significantly preserve viable neurons in the CA1 subfield of hippocampus following SPS exposure, as evidenced by reduced amounts of CA1 neuronal apoptosis. Furthermore, HBO-PC upregulate the expression of TrxR-1 and TrxR-2 mRNA in the hippocampus at 6h and 12h after SPS exposure and ameliorated anxiety-like behavior and cognitive impairments normally induced by SPS. Taken together, these findings suggest that HBO-PC is beneficial for the improvement of anxiety-like behavior and cognitive impairments induced by SPS exposure, and this effect might be associated with inhibition of neuronal apoptosis via upregulation of TrxR in stressed rats.


Subject(s)
Anxiety/therapy , Cognition Disorders/therapy , Hippocampus/metabolism , Hyperbaric Oxygenation , Stress, Physiological , Stress, Psychological , Thioredoxin-Disulfide Reductase/metabolism , Up-Regulation , Analysis of Variance , Animals , Anxiety/metabolism , Apoptosis , Cell Count , Cognition Disorders/metabolism , In Situ Nick-End Labeling , Male , Motor Activity , Neurons/metabolism , RNA, Messenger/metabolism , Random Allocation , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...